Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tegaserod.

L J Scott1, C M Perry

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 24, 1999
PubMed
Summary
This summary is machine-generated.

Tegaserod, a serotonin 5-HT4 receptor agonist, accelerated small bowel transit and improved constipation symptoms in IBS patients. Common side effects included diarrhea and flatulence, with no significant cardiovascular changes observed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of traumatic brain injury amongst secondary school students in England: A retrospective cohort study using electronic health records.

Injury·2026
Same author

Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Drugs·2020
Same author

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Drugs·2020
Same author

Systematic review of interventions for the prevention and treatment of postoperative urinary retention.

BJS open·2019
Same author

Correction to: The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research.

Pilot and feasibility studies·2018
Same author

The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research.

Pilot and feasibility studies·2018
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder.
  • Constipation-predominant IBS (IBS-C) significantly impacts patient quality of life.
  • Serotonin 5-HT4 receptor agonists have been explored for IBS treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of tegaserod in patients with IBS-C.
  • To assess the effect of tegaserod on gastrointestinal transit and symptoms.

Main Methods:

  • A double-blind, placebo-controlled, dose-ranging study.
  • Oral tegaserod (2mg or 6mg twice daily) or placebo administered for one week.
  • Assessment of small bowel transit, colonic emptying, and patient-reported symptoms.

Main Results:

Related Experiment Videos

  • Tegaserod (2mg twice daily) accelerated small bowel transit and increased proximal colonic emptying.
  • Tegaserod (2mg or 6mg twice daily) significantly improved abdominal discomfort, bloating, and constipation.
  • Most frequent adverse events were transient diarrhea and flatulence; no significant cardiovascular changes were noted.

Conclusions:

  • Tegaserod demonstrates efficacy in accelerating gastrointestinal transit and alleviating symptoms in IBS-C patients.
  • Tegaserod is generally well-tolerated, with transient gastrointestinal side effects being most common.
  • Further investigation into tegaserod's therapeutic potential for IBS-C is warranted.